Clinical Trials Browser

Phase 2 × mogamulizumab × 30 days × Clear all

NCT06698003 2026-03-05

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Leukemia, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma